Newer β-lactam and β-lactamase inhibitor combinations available in India: Consensus and controversies

Veeraraghavan, B
July 2011
Indian Journal of Medical Microbiology;Jul2011, Vol. 29 Issue 3, p315
Academic Journal
A letter to the editor is presented which discusses the effectiveness of β-lactamase and β-lactam inhibitor combinations as treatment for Gram-negative bacteria in India.


Related Articles

  • Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies. Merdjan, Henri; Rangaraju, Manickam; Tarral, Antoine // Clinical Drug Investigation;May2015, Vol. 35 Issue 5, p307 

    Background and Objective: Avibactam is a novel non-β-lactam β-lactamase inhibitor effective against Ambler class A, C and some class D β-lactamases that is currently in clinical development in combination with ceftazidime for the treatment of serious Gram-negative infections. It...

  • β-Lactamase inhibition by avibactam in Mycobacterium abscessus. Dubée, Vincent; Bernut, Audrey; Cortes, Mélanie; Lesne, Tiffany; Dorchene, Delphine; Lefebvre, Anne-Laure; Hugonnet, Jean-Emmanuel; Gutmann, Laurent; Mainardi, Jean-Luc; Herrmann, Jean-Louis; Gaillard, Jean-Louis; Kremer, Laurent; Arthur, Michel // Journal of Antimicrobial Chemotherapy (JAC);Apr2015, Vol. 70 Issue 4, p1051 

    Objectives: Two β-lactams, cefoxitin and imipenem, are part of the reference treatment for pulmonary infections with Mycobacterium abscessus. M. abscessus has recently been shown to produce a broad-spectrum β-lactamase, BlaMab, indicating that the combination of β-lactams with a BlaMab...

  • TWO CASES OF IMPORTATION OF NEW DELHI METALLO-β-LACTAMASE 1 INTO NORTHERN IRELAND. Nagar, Aaron; Yew, Peter; Ong, Grace; Black, Claire; Fogarty, Brendan; Christie, Sharon; Hedderwick, Sarah; Kealey, David; Livermore, David M. // Ulster Medical Journal;Sep2012, Vol. 81 Issue 3, p154 

    A letter to the editor is presented about the clinical cases of New Delhi metallo-β-lactamase 1 in Northern Ireland.

  • Once-Daily High-Dose Netilmicin: A New Short-Term Treatment Regimen for Patients with Moderate to Severe Gram-Negative Infections. Boutsikakis, J.; Bassaris, H.; Lazanas, M.; Saroglou, G.; Paniara, O.; Petrikkos, G.; Platsouka, E.; Starakis, J.; Vassiloyiannakopoulos, A.; Antoniadou, A.; Tsagaraki, C.; Skeparni, E.; Goumas, P. // Clinical Drug Investigation;1998, Vol. 15 Issue 3, p205 

    The primary objective of this study was to compare the efficacy and tolerability of a once-daily dose of netilmicin for 3 to 5 days (OD group) vs three times daily for 7 to 14 days (TID group). 93 patients (47 in the OD group and 46 in the TID group), with moderate to severe Gram-negative...

  • Antibiotic pipeline remains limited for pediatrics.  // Infectious Disease News;Dec2012, Vol. 25 Issue 12, p32 

    The article reports on a need to develop new medications with potent gram-negative activity, according to a presenter at the 25th Annual Infectious Diseases in Children Symposium.

  • Parenteral beta-lactamase inhibitor combinations for clinical use. Manzella, John P. // American Family Physician;5/15/1995, Vol. 51 Issue 7, p1695 

    Discusses beta lactamase inhibitors. Production of beta lactamases as an important mechanism through which bacteria become resistant to antibiotics; Inhibitors currently marketed; Bacteria and anaerobic organisms that produce beta-lactamase enzymes.

  • Colistin in the management of severe infections with multidrug resistant Gram-negative bacilli. Streinu-Cercel, Adrian // Germs;Mar2014, Vol. 4 Issue 1, p7 

    The article discusses the use of colistin in the management of severe infections with multidrug resistant Gram-negative bacilli. According to the author, this antibiotic has brought confusion of terms, complexity of pharmacology and contradiction of posology to the medical world. Also discussed...

  • The Evolution of Aminoglycoside Therapv: A Single Daily Dose. Deamer, Robert L.; Dial, Lanyard K. // American Family Physician;4/1/1996, Vol. 53 Issue 5, p1782 

    Focuses on research to determine the optimal aminoglycoside dosage method. Antibiotics for gram-negative infections; Recommendation of one daily dosage; Listing of other antibiotics used in place of aminoglycoside; Toxicity concerns of aminoglycoside; Pharmacologic and clinical basis for one...

  • Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. Muller, Anouk E.; Punt, Nieko; Mouton, Johan W. // Journal of Antimicrobial Chemotherapy (JAC);Apr2013, Vol. 68 Issue 4, p900 

    Objectives The %fT > MIC of ceftazidime has been shown to correlate with microbiological outcome of Gram-negative bacteria (GNB) in preclinical studies. However, clinical data are still lacking. We explored the relationship of ceftazidime exposure and outcome in patients with nosocomial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics